Literature DB >> 29939940

ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.

.   

Abstract

Low-dose aspirin has been used during pregnancy, most commonly to prevent or delay the onset of preeclampsia. The American College of Obstetricians and Gynecologists issued the Hypertension in Pregnancy Task Force Report recommending daily low-dose aspirin beginning in the late first trimester for women with a history of early-onset preeclampsia and preterm delivery at less than 34 0/7 weeks of gestation, or for women with more than one prior pregnancy complicated by preeclampsia. The U.S. Preventive Services Task Force published a similar guideline, although the list of indications for low-dose aspirin use was more expansive. Daily low-dose aspirin use in pregnancy is considered safe and is associated with a low likelihood of serious maternal, or fetal complications, or both, related to use. The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine support the U.S. Preventive Services Task Force guideline criteria for prevention of preeclampsia. Low-dose aspirin (81 mg/day) prophylaxis is recommended in women at high risk of preeclampsia and should be initiated between 12 weeks and 28 weeks of gestation (optimally before 16 weeks) and continued daily until delivery. Low-dose aspirin prophylaxis should be considered for women with more than one of several moderate risk factors for preeclampsia. Women at risk of preeclampsia are defined based on the presence of one or more high-risk factors (history of preeclampsia, multifetal gestation, renal disease, autoimmune disease, type 1 or type 2 diabetes, and chronic hypertension) or more than one of several moderate-risk factors (first pregnancy, maternal age of 35 years or older, a body mass index greater than 30, family history of preeclampsia, sociodemographic characteristics, and personal history factors). In the absence of high risk factors for preeclampsia, current evidence does not support the use of prophylactic low-dose aspirin for the prevention of early pregnancy loss, fetal growth restriction, stillbirth, or preterm birth.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29939940     DOI: 10.1097/AOG.0000000000002708

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  73 in total

1.  Placental Production of Eicosanoids and Sphingolipids in Women Who Developed Preeclampsia on Low-Dose Aspirin.

Authors:  Scott W Walsh; Daniel T Reep; S M Khorshed Alam; Sonya L Washington; Marwah Al Dulaimi; Stephanie M Lee; Edward H Springel; Jerome F Strauss; Daniel J Stephenson; Charles E Chalfant
Journal:  Reprod Sci       Date:  2020-06-17       Impact factor: 3.060

Review 2.  Sleep Disordered Breathing, a Novel, Modifiable Risk Factor for Hypertensive Disorders of Pregnancy.

Authors:  Laura Sanapo; Margaret H Bublitz; Ghada Bourjeily
Journal:  Curr Hypertens Rep       Date:  2020-03-12       Impact factor: 5.369

Review 3.  The role of aspirin and inflammation on reproduction: the EAGeR trial 1.

Authors:  Lindsay D Levine; Tiffany L Holland; Keewan Kim; Lindsey A Sjaarda; Sunni L Mumford; Enrique F Schisterman
Journal:  Can J Physiol Pharmacol       Date:  2018-12-18       Impact factor: 2.273

4.  Is ELABELA a reliable biomarker for hypertensive disorders of pregnancy?

Authors:  Rong Huang; Jing Zhu; Lin Zhang; Xiaolin Hua; Weiping Ye; Chang Chen; Kun Sun; Weiye Wang; Liping Feng; Jun Zhang
Journal:  Pregnancy Hypertens       Date:  2019-06-27       Impact factor: 2.899

5.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

Review 6.  Novel Interventions for the Prevention of Preeclampsia.

Authors:  Marwan Ma'ayeh; Kara M Rood; Douglas Kniss; Maged M Costantine
Journal:  Curr Hypertens Rep       Date:  2020-02-12       Impact factor: 5.369

7.  Preconception Blood Pressure and Its Change Into Early Pregnancy: Early Risk Factors for Preeclampsia and Gestational Hypertension.

Authors:  Carrie J Nobles; Pauline Mendola; Sunni L Mumford; Robert M Silver; Keewan Kim; Victoria C Andriessen; Matthew Connell; Lindsey Sjaarda; Neil J Perkins; Enrique F Schisterman
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

Review 8.  Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines.

Authors:  Rachel G Sinkey; Ashley N Battarbee; Natalie A Bello; Christopher W Ives; Suzanne Oparil; Alan T N Tita
Journal:  Curr Hypertens Rep       Date:  2020-08-27       Impact factor: 5.369

Review 9.  Ischemic stroke and cerebral venous sinus thrombosis in pregnancy.

Authors:  Hannah J Roeder; Jean Rodriguez Lopez; Eliza C Miller
Journal:  Handb Clin Neurol       Date:  2020

10.  Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension.

Authors:  Chaitra Banala; Sindy Moreno; Yury Cruz; Rupsa C Boelig; Gabriele Saccone; Vincenzo Berghella; Corina N Schoen; Amanda Roman
Journal:  Am J Obstet Gynecol       Date:  2020-03-12       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.